Gilead Sciences, Inc. (NASDAQ: GILD) announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice‑yearly lenacapavir for HIV prevention as pre‑exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. The partnership establishes a coordinated regional pathway to expand long‑acting HIV prevention as part of broader efforts to end the epidemic in the region.
Agreement Snapshot
| Item | Detail |
|---|---|
| Parties | Gilead Sciences (NASDAQ: GILD) & Pan American Health Organization (PAHO) |
| Announcement Date | 16 September 2026 |
| Product | Lenacapavir – twice‑yearly injectable for HIV PrEP |
| Geographic Scope | All PAHO Member States in Latin America and the Caribbean |
| Access Mechanism | PAHO’s Regional Revolving Funds |
| Objective | Accelerate adoption and implementation of long‑acting HIV prevention; support country‑led efforts toward ending the epidemic |
Product Profile – Lenacapavir for PrEP
- Molecule: Lenacapavir, a long‑acting capsid inhibitor targeting the HIV capsid protein at multiple stages of the viral lifecycle.
- Dosing Regimen: Twice‑yearly subcutaneous injection — a major adherence advantage over daily oral PrEP for at‑risk populations.
- Indication in Focus: HIV pre‑exposure prophylaxis (PrEP), preventing infection in HIV‑negative individuals.
- Public Health Rationale: Long‑acting prevention reduces the adherence burden that limits real‑world effectiveness of daily regimens, particularly in hard‑to‑reach and high‑risk communities.
Regional Access Pathway – PAHO Revolving Funds
- Coordinated Procurement: Through PAHO’s Regional Revolving Funds, the agreement creates a coordinated regional pathway for Member States to access lenacapavir PrEP, pooling demand and streamlining procurement.
- Country‑Led Implementation: The framework supports country‑led efforts toward adoption and implementation, allowing national programs to integrate long‑acting PrEP into existing HIV prevention strategies.
- Epidemic-Ending Ambition: The initiative forms part of broader regional efforts to end the HIV epidemic across Latin America and the Caribbean.
- Commercial Terms: Pricing, supply volumes, and rollout timelines under the agreement not disclosed.
Market Impact & Outlook
- Global Access Strategy: The PAHO agreement extends the geographic reach of twice‑yearly lenacapavir PrEP beyond earlier access initiatives, positioning the long‑acting injectable as a cornerstone of regional HIV prevention in Latin America and the Caribbean.
- Public-Health Scale: A revolving‑fund mechanism covering all PAHO Member States offers a scalable model for financing long‑acting prevention across dozens of national programs simultaneously.
- Adherence Advantage: By removing the daily‑pill burden, lenacapavir PrEP could materially improve real‑world prevention coverage among key populations where adherence challenges drive new infections.
- Strategic Positioning: For Gilead, sustained institutional partnerships with multilateral health organizations reinforce its leadership in long‑acting HIV prevention as the field shifts from treatment toward prevention‑first strategies.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding access expansion, country adoption and implementation timelines, and public‑health impact expectations for lenacapavir PrEP under the Gilead–PAHO agreement. Actual results may differ due to risks including regulatory approvals in individual Member States, procurement and supply execution, program funding, and epidemiological dynamics across the region.-Fineline Info & Tech
